Alessandro Rambaldi
ASST Papa Giovanni XXIII · ASST - Papa Giovanni XXIII · A.O. Ospedale Papa Giovanni XXIII
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alessandro Rambaldi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:14 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03922100 · Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMMLNerviano Medical Sciences · terminated · Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) · principal investigator
- Ph1NCT03823365 · Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic LeukemiaA.O. Ospedale Papa Giovanni XXIII · unknown · Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia · principal investigator
- Ph1/Ph2NCT03821519 · Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell TransplantA.O. Ospedale Papa Giovanni XXIII · unknown · Relapsed Hematologic Malignancy · principal investigator
- Ph2NCT03367299 · Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic LeukemiaGruppo Italiano Malattie EMatologiche dell'Adulto · completed · Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor · study director
- N/ANCT03131531 · Bergamo Lymphoid Cancer RegistryA.O. Ospedale Papa Giovanni XXIII · recruiting · Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloma · principal investigator
- Ph1NCT02565459 · MSC and Kidney Transplant Tolerance (Phase A)Monia Lorini · unknown · Chronic Renal Failure · principal investigator
- Ph1NCT02260375 · MSC Therapy in Liver TransplantationMonia Lorini · unknown · Liver Transplant Rejection · principal investigator
- Ph1/Ph2NCT02032446 · Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host DiseaseA.O. Ospedale Papa Giovanni XXIII · unknown · Hematologic Malignancies · principal investigator
- Ph1NCT02012153 · Mesenchymal Stromal Cells in Kidney Transplant RecipientsMario Negri Institute for Pharmacological Research · terminated · Kidney Transplant Rejection · principal investigator
- Ph1NCT01764880 · SST0001 (Roneparstat) in Advanced Multiple MyelomaSigma Tau Research Switzerland SA · completed · Multiple Myeloma · principal investigator
- Ph2NCT01761968 · Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative NeoplasmsItalfarmaco · active not recruiting · Chronic Myeloproliferative Neoplasms · principal investigator
- Ph2NCT01681563 · Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic LeukemiaNiguarda Hospital · completed · Chronic Lymphocytic Leukemia · principal investigator
- Ph1NCT01275612 · Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ CancersMario Negri Institute for Pharmacological Research · withdrawn · Solid Tumors, Acute Kidney Injury · principal investigator
- Ph2NCT01259817 · Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)Ronald Hoffman · completed · High Risk Polycythemia Vera, High Risk Essential Thrombocythemia · principal investigator
- Ph2NCT00928707 · Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia VeraItalfarmaco · completed · Polycythemia Vera · principal investigator
- Ph1/Ph2NCT00752479 · Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant ToleranceMario Negri Institute for Pharmacological Research · terminated · Kidney Transplant · principal investigator
- Ph2NCT00606307 · Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative DiseasesItalfarmaco · completed · Myeloproliferative Diseases · principal investigator
- Ph2/Ph3NCT00354120 · Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic TransplantGruppo Italiano Trapianto di Midollo Osseo · completed · Acute Myeloblastic Leukemia, Lymphoblastic Leukemia, Myelodysplasia · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 18:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Project 3: Development of Strategies to Deplete Myelofibrosis Stem CellsP01CA108671 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ronald Hoffman · fiscal years 2006 to 2026Named on NCT01259817
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 18:14 UTC. The ranking covers the 200 most relevant of 127 PubMed records, and a shared surname and initials can bring in a namesake. All 127 on PubMed
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.N Engl J Med · 20212,208 citationsRCR 120.1
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.N Engl J Med · 20171,774 citationsRCR 54.7
- Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.N Engl J Med · 20131,290 citationsRCR 34.9
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Lancet Oncol · 20151,054 citationsRCR 30.0
- 451 citationsRCR 18.1
- 365 citationsRCR 11.0
- 325 citationsRCR 8.3
- 312 citationsRCR 9.9
- 267 citationsRCR 6.7
- Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.N Engl J Med · 2015265 citationsRCR 6.8